Publication | Closed Access

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers

Breast OncologyMedicinePathologyImmune Checkpoint InhibitorBreast CancerTriple-negative Breast CancerBrca1 Mutation CarriersCancer TreatmentAnti-cancer AgentOncologyRadiation OncologyNeo-adjuvant Doxorubicin